デジタルバイオマーカー市場規模、シェア、動向、2031年までの世界予測

世界のデジタルバイオマーカー市場は2026年に74億1,000万米ドル規模となり、年平均成長率（CAGR）19.1%で成長し、2031年には177億3,000万米ドルに達するとMarketsandMarketsでは予測しています。

デジタルバイオマーカー市場はデータ駆動型臨床試験の急速な進化と、臨床試験へのデジタルヘルス技術の統合の成長傾向が促進要因となっています。製薬会社やバイオテクノロジー企業は、継続的かつ客観的な患者モニタリングを可能にするために、臨床試験のさまざまな段階でデジタルバイオマーカーの使用を増やしており、これによりデータ品質とエンドポイントの精度が向上しています。これは、実世界のデータが薬剤の有効性を判断する上で重要な役割を果たす、より効率的で患者中心の臨床試験への大きなトレンドの一部です。同時に、ウェアラブルデバイスやセンサー技術などの遠隔データ収集技術を使用してデータをより頻繁に収集する、より分散型の臨床試験へのトレンドが高まっています。これは、臨床試験におけるデジタルバイオマーカーソフトウェア技術の普及という大きなトレンドの一部です。

MarketsandMarkets（マーケッツアンドマーケッツ）「デジタルバイオマーカー市場 – タイプ（生理的、音声的、特異体質的）、治療［心臓、腫瘍（肺がん、乳がん）、精神保健、神経］、用途［臨床研究（第IV相）］、エンドユーザー（製薬・バイオテクノロジー企業、CRO）－2031年までの世界予測 – Digital Biomarkers Market by Type (Physiological, Vocal, Idiosyncratic), Therapy [Cardio, Onco (Lung, Breast Cancer), Mental Health, Neuro], Application [Clinical Research (Phase IV)], End User (Pharma & Biotech Companies, CROs) – Global Forecast to 2031」はデジタルバイオマーカーの世界市場を調査し、主要セグメント別に分析・予測を行っています。

主な掲載内容

• 市場概観
  • 市場力学
  • アンメットニーズとホワイトスペース
  • 連結市場と異業種間連携機会
  • ティア1、ティア2、ティア3プレイヤ別戦略的行動
• 業界動向
  • ファイブフォース
  • マクロ経済指標
  • サプライチェーン分析
  • エコシステム分析
  • 価格分析
  • 主要会議とイベント　2026-2027年
  • 顧客ビジネスに影響を与える動向／ディスラプション
  • 投資と資金調達シナリオ
  • ケーススタディ分析
  • 2025年の米国の関税措置がデジタルバイオマーカー市場に与える影響
• 顧客ランドスケープと購入者行動
  • 意思決定プロセス
  • 主要ステークホルダーと購入評価基準
  • 採用の障壁と内部での課題
  • 多方面でのエンドユース産業からのアンメットニーズ
  • 市場収益性
• 法規制環境
  • 地域別法規制とコンプライアンス
• 技術、特許、AI導入における戦略的ディスラプション
  • 重要新興技術
  • 補完技術
  • 関連技術
  • 技術／製品ロードマップ
  • 特許分析
  • 今後の用途
  • デジタルバイオマーカー市場にAI／生成AIが与える影響
• タイプ別デジタルバイオマーカー市場
  • 生理学的バイオマーカー
  • 個別化バイオマーカー
  • 認知バイオマーカー
  • 音声バイオマーカー
  • その他のバイオマーカー
• 治療領域別デジタルバイオマーカー市場
  • 心血管疾患
  • 腫瘍学
  • 糖尿病
  • メンタルヘルスと行動健康
  • 呼吸器疾患
  • ライフスタイルと健康増進
  • 神経学
  • 筋骨格系疾患／疼痛管理
  • 女性の健康と生殖医療
  • その他の疾患
• 用途別デジタルバイオマーカー市場
  • 臨床研究
  • 臨床ケア
• エンドユーザ別デジタルバイオマーカー市場
  • 製薬会社＆バイオテクノロジー企業
  • 医薬品開発受託機関（CRO）
  • 病院＆専門クリニック
  • その他のエンドユーザ
• 地域別デジタルバイオマーカー市場
  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • その他の欧州
  • ラテンアメリカ
    • ブラジル
    • その他のラテンアメリカ
  • アジア太平洋地域
    • 中国
    • 日本
    • インド
    • オーストラリア
    • 韓国
    • その他のアジア太平洋地域
  • 中東＆アフリカ
    • GCC諸国
    • サウジアラビア
    • アラブ首長国連邦（UAE）
    • その他
  • 南アフリカ
  • その他の中東＆アフリカ
• 競合勢力図
  • 主要プレイヤーの戦略／勝つ権利
  • 上位の市場プレイヤの収益シェア分析　2025年
  • ブランド比較
  • 企業評価と財政メトリクス
  • 企業評価マトリクス
  • 企業評価マトリクス：スタートアップ／中小企業　2025年
  • 競合シナリオ
• 企業情報

調査対象企業

• IXICO PLC（英国）
• Ametris, LLC（米国）
• Empatica, Inc.（米国）
• AliveCor, Inc.（米国）
• CONNEQT Health（米国）
• VivoSense（米国）
• BioSensics（米国）
• Lunit, Inc.（韓国）

調査範囲：

この調査レポートでは、デジタルバイオマーカー市場を、タイプ（生理学的バイオマーカー、特異体質性バイオマーカー、認知バイオマーカー、音声バイオマーカー、その他のバイオマーカー）、治療領域（心血管疾患［動脈硬化性心血管疾患（ASCVD）／二次予防、心不全（HFrEFおよびHFpEF）、高血圧、心房細動（AF）／脳卒中予防、肺高血圧、構造的心疾患／インターベンショナル心臓病学］、腫瘍学（固形腫瘍、血液悪性腫瘍）、糖尿病、メンタルヘルスおよび行動健康、呼吸器疾患、ライフスタイルおよび健康増進、神経学、筋骨格系疾患／疼痛管理、女性の健康と生殖健康、その他の疾患］、アプリケーション［臨床研究アプリケーション（第II相、第III相、第IV相）および臨床ケアアプリケーション］、エンドユーザー［製薬会社およびバイオテクノロジー企業、医薬品開発業務受託機関（CRO）、病院および専門医療機関］に分類しています。診療所、その他（研究機関などを含む）]、および地域（北米、ヨーロッパ、アジア太平洋、ラテンアメリカ、中東およびアフリカ）

本レポートでは、デジタルバイオマーカー市場の成長に影響を与える主要な要因（推進要因、阻害要因、課題、機会など）に関する詳細な情報を提供します。主要な業界プレーヤーの詳細な分析を行い、事業概要、ソリューションとサービス、契約、パートナーシップ、協定、製品・サービスの発売、合併・買収、およびデジタルバイオマーカー市場に関連する最近の動向に関する洞察を提供します。また、デジタルバイオマーカー市場のエコシステムにおける新興スタートアップ企業の競合分析も本レポートで取り上げています。

本レポートを購入する理由：

本レポートは、デジタルバイオマーカー市場および各サブセグメントの収益予測に関する最も正確な情報を提供することで、市場リーダーや新規参入企業を支援します。また、関係者が競争環境を理解し、より的確な事業展開と適切な市場参入戦略の策定に役立つ洞察を得るのに役立ちます。さらに、市場の動向を把握し、主要な市場促進要因、阻害要因、課題、機会に関する情報を提供します。

本レポートは、以下のポイントに関する洞察を提供します。

デジタルバイオマーカー市場の成長に影響を与える主要な推進要因（スマートフォン、ウェアラブルデバイス、コネクテッドヘルスエコシステムの拡大、分散型および遠隔臨床試験の拡大、継続的なモニタリングを必要とする慢性疾患の罹患率の上昇、AIおよびデジタルヘルス分析の進歩）、阻害要因（健康データに関連するデータプライバシーとセキュリティの懸念、患者のデジタルリテラシーとテクノロジーへのアクセスの制限）、機会（医薬品開発および臨床試験エンドポイントにおけるデジタルバイオマーカーの使用増加、精密医療および個別化医療の成長、神経疾患および精神疾患モニタリングにおける新たな応用）、課題（デジタルバイオマーカーの標準化された検証フレームワークの欠如、デジタルエンドポイントおよびバイオマーカー検証に関する規制上の不確実性）の分析

• 製品開発／イノベーション：デジタルバイオマーカー市場における今後のテクノロジー、研究開発活動、製品およびサービスの発売に関する詳細な洞察
• 市場開発：さまざまな地域における有望な市場に関する包括的な情報
• 市場の多様化：未開拓の製品およびサービスに関する包括的な情報デジタルバイオマーカー市場の地域別動向、最新動向、および投資状況
• 競合分析：デジタルバイオマーカー市場における主要企業（IXICO PLC（英国）、Ametris, LLC（米国）、Empatica, Inc.（米国）、AliveCor, Inc.（米国）、CONNEQT Health（米国）、VivoSense（米国）、BioSensics（米国）、Lunit, Inc.（韓国）など）の市場シェア、成長戦略、およびサービス提供内容を詳細に分析

Report Description

The global digital biomarkers market is projected to reach USD 17.73 billion by 2031, growing from USD 7.41 billion in 2026 at a CAGR of 19.1%. The digital biomarkers market is being driven by the rapid evolution of data-driven clinical trials and the growing trend of integrating digital health technology into clinical trials. Pharmaceutical and biotech companies are increasingly using digital biomarkers in various stages of clinical trials to enable continuous and objective patient monitoring, thus improving data quality and endpoint accuracy. This is a part of a larger trend towards more efficient and patient-centric clinical trials, in which data from real-world sources plays a crucial role in determining the effectiveness of a drug. At the same time, there is a growing trend toward more decentralized clinical trials, in which data is collected more frequently by using remote data collection technology such as wearable devices and sensor technology. This is a part of a larger trend towards more digital biomarker software technology in clinical trials.

“By type, the physiological biomarkers segment is expected to account for the largest market share of the digital biomarkers market during the forecast period.”

By type, the physiological biomarkers segment is expected to hold the largest share of the digital biomarkers market during the forecast period. This is mainly due to the widespread use of continuous physiological measures like heart rate, ECG, respiratory rate, and activity levels in various clinical research and patient care settings. Physiological biomarkers are scalable and are well validated, making them more suitable for remote patient monitoring and chronic disease management. In addition, the growing trend of using software platforms and AI-based tools associated with wearable devices is further propelling their adoption, particularly in cardiovascular and metabolic conditions where continuous monitoring is critical in making clinical decisions. This is also evident from published research that states that physiological data streams like heart rate and activity levels are some of the most commonly used digital endpoints in clinical trials, mainly due to their objectivity and ability to provide high-frequency and real-world data. In addition, the move towards decentralized trials and RWE generation is also further solidifying their position in the field of digital biomarkers, as they allow for patient monitoring outside traditional clinical environments.

In June 2025, AliveCor, Inc. (US) partnered with the British Heart Foundation (UK), donating proceeds from its KardiaMobile 6L device to support cardiovascular research and promote the adoption of digital heart rhythm monitoring technologies. These examples further hint at the growing role of physiological digital biomarkers in advancing cardiac care and research.

“By end user, the hospitals & specialty clinics segment is expected to achieve the fastest growth during the forecast period.”

By end user, the hospitals & specialty clinics segment is expected to witness the highest growth in the digital biomarkers market over the forecast period. The growth in this segment can be attributed to the rising adoption of digital biomarkers in hospitals and specialty clinics for real-time patient monitoring. Digital biomarkers are being increasingly integrated into the workflows of hospitals and specialty clinics for data-driven decision-making. Hospitals and specialty clinics are adopting wearable-enabled platforms and artificial intelligence-based analytics solutions for continuously monitoring physiological, cognitive, and behavioral changes in patients. Digital biomarkers help hospitals and specialty clinics in continuously monitoring patient data in real-time, thus helping in the early detection of changes in patient health. Moreover, the rising trend of value-based care is fueling the adoption of remote monitoring solutions in hospitals and specialty clinics. The rising prevalence of chronic diseases such as cardiovascular diseases, neurological disorders, and diabetes is also contributing to the growth of the digital biomarkers market in hospitals and specialty clinics. The rising trend of health information technology, which allows for seamless integration of digital biomarker solutions into electronic health records, is also fueling the growth of the digital biomarkers market in hospitals and specialty clinics.

“Asia Pacific to witness the highest growth rate during the forecast period.”

The digital biomarkers market in Asia Pacific is growing rapidly, with the region witnessing high growth in the expansion of clinical research activities. The region is witnessing the incorporation of digital technologies into the healthcare infrastructure. Countries such as India, South Korea, Japan, and Australia are gaining importance as hubs for clinical research activities. Due to the improvement in the regulatory environment and the cost advantage, the pharmaceutical and biotech industries are increasingly using the Asia Pacific as a hub for conducting clinical research activities. As the pharmaceutical and biotech industries increasingly rely on digital technologies to conduct clinical research activities, the digital biomarkers market is growing rapidly.

Asia Pacific is witnessing the incorporation of digital technologies into the healthcare infrastructure. The region is witnessing the expansion of clinical research activities. In November 2025, Lunit Inc., a South Korean-based company, announced its collaboration with Labcorp to conduct research using digital pathology technology powered by artificial intelligence and expand access to imaging-based biomarkers for clinical and translational oncology research globally. Such developments indicate the potential of the region as a lucrative market for digital biomarkers.

The breakdown of primary participants is as follows:

• By Company Type – Tier 1 Companies: 60%, Tier 2 Companies: 30%, and Tier 3 Companies: 10%
• By Designation – C-level Executives: 30%, Director-level Personnel: 50%, and Other Designations: 20%
• By Region – North America: 45%, Europe: 20%, Asia Pacific: 25%, Rest of the world: 10%

IXICO PLC (UK), Ametris, LLC (US), and Empatica, Inc. (US) are some of the key players in the digital biomarkers market. The study includes an in-depth competitive analysis of these key players, their company profiles, recent developments, and key market strategies.

Research Coverage:

This research report categorizes the digital biomarkers market by type (physiological biomarkers, idiosyncratic biomarkers, cognitive biomarkers, vocal biomarkers, and other biomarkers), therapeutic area {cardiovascular [atherosclerotic cardiovascular disease (ASCVD)/secondary prevention, heart failure (HFrEF and HFpEF), hypertension, atrial fibrillation (AF)/stroke prevention, pulmonary hypertension, and structural heart disease/interventional cardiology], oncology (solid tumors, hematologic malignancies), diabetes, mental health & behavioral health, respiratory disorders, lifestyle & wellness improvement, neurology, musculoskeletal disorders/pain management, women’s health & reproductive health, and other diseases}, application, [clinical research applications (phase II, phase III, phase IV) and clinical care applications], end user [pharmaceutical and biotechnology companies, contract research organizations (CROs), hospitals and specialty clinics, and others (including research institutes, etc.)] and region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa).

The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the digital biomarkers market. A detailed analysis of the key industry players has been done to provide insights into their business overview; solutions and services; contracts, partnerships, agreements, product & service launches, mergers & acquisitions; and recent developments associated with the digital biomarkers market. Competitive analysis of upcoming startups in the digital biomarkers market ecosystem is covered in this report.

Reasons to Buy this Report:

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the digital biomarkers market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.

The report provides insights into the following pointers:

• Analysis of key drivers (Expansion of smartphones, wearables, and connected health ecosystems; expansion of decentralized and remote clinical trials; rising prevalence of chronic diseases requiring continuous monitoring; advancements in AI and digital health analytics) restraints (Data privacy and security concerns related to health data, limited digital literacy and technology access among patients) opportunities (Increasing use of digital biomarkers in drug development and clinical trial endpoints, growth of precision medicine and personalized healthcare, emerging applications in neurological and mental health monitoring), challenges (Lack of standardized validation frameworks for digital biomarkers, regulatory uncertainty around digital endpoints and biomarker validation) influencing the growth of the digital biomarkers market
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and product & service launches in the digital biomarkers market
• Market Development: Comprehensive information about lucrative markets across varied regions
• Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the digital biomarkers market
• Competitive Assessment: In-depth assessment of market share, growth strategies, and service offerings of leading players, namely IXICO PLC (UK), Ametris, LLC (US), Empatica, Inc. (US), AliveCor, Inc. (US), CONNEQT Health (US), VivoSense (US), BioSensics (US), Lunit, Inc. (South Korea), among others, in the digital biomarkers market

Table of Contents

1 INTRODUCTION 35

1.1 STUDY OBJECTIVES 35
1.2 MARKET DEFINITION 35
1.3 MARKET SCOPE 36
1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE 36
1.3.2 INCLUSIONS & EXCLUSIONS 37
1.3.3 YEARS CONSIDERED 38
1.4 CURRENCY CONSIDERED 38
1.5 LIMITATIONS 39
1.6 STAKEHOLDERS 39

2 EXECUTIVE SUMMARY 41

2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS 41
2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS 43
2.3 DISRUPTIVE TRENDS SHAPING THE MARKET 44
2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 45
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 46

3 PREMIUM INSIGHTS 47

3.1 DIGITAL BIOMARKERS MARKET OVERVIEW 47
3.2 DIGITAL BIOMARKERS MARKET, BY APPLICATION & REGION 48
3.3 DIGITAL BIOMARKERS MARKET: GEOGRAPHIC SNAPSHOT 48

4 MARKET OVERVIEW 49

4.1 INTRODUCTION 49
4.2 MARKET DYNAMICS 50
4.2.1 DRIVERS 50
4.2.1.1 Expansion of smartphones, wearables, and connected health ecosystems 50
4.2.1.2 Expansion of decentralized and remote clinical trials 51
4.2.1.3 Rising prevalence of chronic diseases that require continuous monitoring 52
4.2.1.4 Advancements in AI and digital health analytics 52
4.2.2 RESTRAINTS 53
4.2.2.1 Data privacy and cybersecurity concerns 53
4.2.2.2 Limited digital literacy and technology access among patients 53
4.2.3 OPPORTUNITIES 54
4.2.3.1 Increasing use in drug development and clinical trial endpoints 54
4.2.3.2 Growth of precision medicine and personalized healthcare 54
4.2.3.3 Emerging applications in neurological and mental health monitoring 55
4.2.4 CHALLENGES 55
4.2.4.1 Lack of standardized validation frameworks for digital biomarkers 55
4.2.4.2 Regulatory uncertainty around digital endpoints and biomarker validation 55
4.3 UNMET NEEDS AND WHITE SPACES 56
4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES 56
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 57

5 INDUSTRY TRENDS 58

5.1 PORTER’S FIVE FORCES ANALYSIS 58
5.1.1 BARGAINING POWER OF SUPPLIERS (MODERATE) 59
5.1.2 BARGAINING POWER OF BUYERS (HIGH) 59
5.1.3 THREAT OF SUBSTITUTES (MODERATE TO HIGH) 59
5.1.4 THREAT OF NEW ENTRANTS (MODERATE) 59
5.1.5 INTENSITY OF COMPETITIVE RIVALRY (HIGH) 60
5.2 MACROECONOMIC INDICATORS 60
5.2.1 INTRODUCTION 60
5.2.2 GDP TRENDS AND FORECAST 60
5.2.3 TRENDS IN GLOBAL HEALTHCARE IT INDUSTRY 60
5.3 SUPPLY CHAIN ANALYSIS 61
5.4 ECOSYSTEM ANALYSIS 62
5.5 PRICING ANALYSIS 64
5.5.1 INDICATIVE PRICE FOR DIGITAL BIOMARKERS, BY KEY PLAYER (2025) 64
5.5.2 INDICATIVE PRICE FOR DIGITAL BIOMARKERS, BY REGION (2025) 65
5.6 KEY CONFERENCES AND EVENTS, 2026–2027 65
5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 67
5.8 INVESTMENT AND FUNDING SCENARIO 67
5.9 CASE STUDY ANALYSIS 68
5.10 IMPACT OF 2025 US TARIFF ON DIGITAL BIOMARKERS MARKET 70
5.10.1 INTRODUCTION 70
5.10.2 KEY TARIFF RATES 71
5.10.3 PRICE IMPACT ANALYSIS 72
5.10.4 IMPACT ON COUNTRY/REGION 72
5.10.4.1 US 72
5.10.4.2 Europe 72
5.10.4.3 Asia Pacific 73
5.10.5 IMPACT ON END USERS 73
5.10.5.1 Pharmaceutical and biotechnology companies 73
5.10.5.2 Contract research organizations 73
5.10.5.3 Hospitals and specialty clinics 73
5.10.5.4 Others (research institutes, etc.) 74

6 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 75

6.1 INTRODUCTION 75
6.2 DECISION-MAKING PROCESS 75
6.3 KEY STAKEHOLDERS AND BUYING EVALUATION CRITERIA 75
6.3.1 KEY STAKEHOLDERS IN BUYING PROCESS 75
6.3.2 BUYING CRITERIA 76
6.4 ADOPTION BARRIERS & INTERNAL CHALLENGES 77
6.5 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 78
6.5.1 UNMET NEEDS 78
6.5.2 END USER EXPECTATIONS 79
6.6 MARKET PROFITABILITY 79

7 REGULATORY LANDSCAPE 80

7.1 REGIONAL REGULATIONS AND COMPLIANCE 80
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, & OTHER ORGANIZATIONS 81
7.1.2 REGULATORY FRAMEWORK 85
7.1.2.1 North America 85
7.1.2.2 Europe 86
7.1.2.3 Asia Pacific 87
7.1.2.4 Latin America 88
7.1.2.5 Middle East & Africa 88
7.1.3 INDUSTRY STANDARDS 89

8 STRATEGIC DISRUPTION THROUGH TECHNOLOGY, PATENTS, AND AI ADOPTION 90

8.1 KEY EMERGING TECHNOLOGIES 90
8.1.1 WEARABLE SENSOR TECHNOLOGIES 90
8.1.2 ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING ANALYTICS 90
8.1.3 MOBILE HEALTH (MHEALTH) PLATFORMS AND SMARTPHONE SENSORS 90
8.2 COMPLEMENTARY TECHNOLOGIES 91
8.2.1 INTERNET OF MEDICAL THINGS (IOMT) 91
8.2.2 TELEHEALTH AND REMOTE PATIENT MONITORING 91
8.3 ADJACENT TECHNOLOGIES 91
8.3.1 DIGITAL THERAPEUTICS 91
8.3.2 DIGITAL PATHOLOGY AND IMAGING AI 92
8.4 TECHNOLOGY/PRODUCT ROADMAP 92
8.5 PATENT ANALYSIS 93
8.5.1 PATENT PUBLICATION TRENDS IN DIGITAL BIOMARKERS MARKET 93
8.5.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS 94

8.6 FUTURE APPLICATIONS 96
8.6.1 AI-ENABLED INTELLIGENT SCREENING AND INTERPRETATION 97
8.6.2 CONTINUOUS AND PREDICTIVE HEALTH MONITORING APPLICATIONS 97
8.6.3 DECENTRALIZED, REMOTE, AND REAL-WORLD DATA ECOSYSTEMS 97
8.7 IMPACT OF AI/GEN AI ON DIGITAL BIOMARKERS MARKET 97
8.7.1 INTRODUCTION 97
8.7.2 MARKET POTENTIAL OF AI/GEN AI IN DIGITAL BIOMARKERS MARKET 98
8.7.3 CASE STUDIES RELATED TO AI/GEN AI IMPLEMENTATION 100
8.7.3.1 Early Alzheimer’s detection using mobile-based cognitive assessment platforms 100
8.7.4 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS 100
8.7.4.1 Digital health market 101
8.7.4.2 Remote patient monitoring market 101
8.7.4.3 Telehealth & telemedicine market 101
8.7.5 USER READINESS AND IMPACT ASSESSMENT 101
8.7.5.1 User readiness 101
8.7.5.1.1 User A: Pharmaceutical & biotechnology companies 101
8.7.5.1.2 User B: Contract research organizations (CROs) 102
8.7.5.2 Impact assessment 102
8.7.5.2.1 User A: Pharmaceutical & biotechnology companies 102
8.7.5.2.1.1 Implementation 102
8.7.5.2.1.2 Impact 102
8.7.5.2.2 User B: Contract research organizations 102
8.7.5.2.2.1 Implementation 102
8.7.5.2.2.2 Impact 103

9 DIGITAL BIOMARKERS MARKET, BY TYPE 104

9.1 INTRODUCTION 105
9.2 PHYSIOLOGICAL BIOMARKERS 105
9.2.1 SEGMENT LEADS MARKET ADOPTION THROUGH CLINICAL VALIDATION AND AI-DRIVEN ANALYTICS 105
9.3 IDIOSYNCRATIC BIOMARKERS 107
9.3.1 PRECISION MEDICINE DRIVEN THROUGH PERSONALIZED, INDIVIDUAL-LEVEL DATA INSIGHTS 107
9.4 COGNITIVE BIOMARKERS 109
9.4.1 ENABLE SCALABLE AND OBJECTIVE MEASUREMENT OF NEUROLOGICAL FUNCTION THROUGH ADVANCED ANALYTICS 109
9.5 VOCAL BIOMARKERS 110
9.5.1 AI-POWERED VOICE ANALYSIS ENABLES SCALABLE MENTAL HEALTH MONITORING 110
9.6 OTHER BIOMARKERS 112

10 DIGITAL BIOMARKERS MARKET, BY THERAPEUTIC AREA 114

10.1 INTRODUCTION 115
10.2 CARDIOVASCULAR 115
10.2.1 ATHEROSCLEROTIC CARDIOVASCULAR DISEASE/SECONDARY PREVENTION 117
10.2.1.1 Continuous risk monitoring and predictive insights in cardiovascular disease management – key driver 117
10.2.2 HEART FAILURE (HFREF & HFPEF) 118
10.2.2.1 Demand driven by advanced early detection and remote monitoring in heart failure management 118
10.2.3 HYPERTENSION 119
10.2.3.1 Transforming blood pressure assessment from episodic to continuous monitoring 119
10.2.4 ATRIAL FIBRILLATION/STROKE PREVENTION 120
10.2.4.1 Unlocking subclinical AF identification via long-duration rhythm analytics 120
10.2.5 PULMONARY HYPERTENSION 121
10.2.5.1 Advancement of functional endpoint measurement beyond traditional walk tests to boost growth 121
10.2.6 STRUCTURAL HEART DISEASE/INTERVENTIONAL CARDIOLOGY 121
10.2.6.1 Remote post-procedural surveillance in structural heart interventions to drive segment 121
10.3 ONCOLOGY 122
10.3.1 SOLID TUMORS 124
10.3.1.1 BREAST CANCER 125
10.3.1.1.1 Segment driven by enhanced tumor characterization through AI-driven imaging and pathology analytics 125
10.3.1.2 LUNG CANCER 126
10.3.1.2.1 Enhanced immunotherapy response prediction using imaging biomarkers to boost growth 126
10.3.1.3 Prostate cancer 127
10.3.1.3.1 Segment growth propelled by reduced variability in cancer grading with quantitative digital pathology 127
10.3.1.4 COLORECTAL CANCER 127
10.3.1.4.1 Enhanced gastrointestinal oncology trials with decentralized functional endpoints – major driver 127
10.3.1.5 BRAIN TUMOR 128
10.3.1.5.1 Enhanced tumor monitoring with advanced MRI and volumetric analytics 128
10.3.1.6 OTHER SOLID TUMORS 129
10.3.1.6.1 Extension of digital biomarker utility across rare and heterogeneous tumor types to drive segment 129
10.3.2 HEMATOLOGIC MALIGNANCIES 130
10.3.2.1 LEUKEMIA 131
10.3.2.1.1 Enhanced MRD detection and quantification through AI-driven analytics to boost market 131
10.3.2.2 LYMPHOMA 132
10.3.2.2.1 Capturing immune response dynamics with continuous digital monitoring – key benefit 132
10.3.2.3 MULTIPLE MYELOMA 133
10.3.2.3.1 Segment growth driven by enhanced disease burden assessment with integrated imaging and pathology analytics 133
10.3.2.4 OTHER HEMATOLOGIC MALIGNANCIES 134
10.3.2.4.1 High-sensitivity endpoint generation in small patient populations to boost market 134
10.4 DIABETES 135
10.4.1 CONTINUOUS MONITORING PLATFORMS EXPANDING INTO HOLISTIC CARDIOMETABOLIC RISK PREDICTION 135
10.5 MENTAL HEALTH & BEHAVIORAL HEALTH 137
10.5.1 PASSIVE BEHAVIORAL AND VOICE DATA ENABLE SCALABLE OBJECTIVE CONDITION MONITORING 137
10.6 RESPIRATORY DISORDERS 138
10.6.1 EARLY EXACERBATION DETECTION THROUGH CONTINUOUS MONITORING REDUCES HOSPITALIZATIONS AND COSTS 138
10.7 LIFESTYLE & WELLNESS IMPROVEMENT 140
10.7.1 EXPANDING PREVENTIVE HEALTH THROUGH CONTINUOUS BEHAVIORAL DATA INSIGHTS 140
10.8 NEUROLOGY 142
10.8.1 REGULATORY VALIDATION OF DIGITAL ENDPOINTS TO ACCELERATE EARLY DETECTION AND TRIAL ADOPTION 142
10.9 MUSCULOSKELETAL DISORDERS/PAIN MANAGEMENT 144
10.9.1 EMPLOYER-BACKED DIGITAL CARE AND MOTION TRACKING TO DRIVE SCALABLE REHABILITATION SOLUTIONS 144
10.10 WOMEN’S HEALTH & REPRODUCTIVE HEALTH 146
10.10.1 ADDRESSING UNMET NEEDS THROUGH DATA-DRIVEN WOMEN’S HEALTH INSIGHTS 146
10.11 OTHER DISEASES 148
10.11.1 EXPANDING USE CASES TO DRIVE ADOPTION ACROSS CHRONIC AND UNDERSERVED CONDITIONS 148

11 DIGITAL BIOMARKERS MARKET, BY APPLICATION 149

11.1 INTRODUCTION 150
11.2 CLINICAL RESEARCH 150
11.2.1 PHASE II 152
11.2.1.1 Critical role in early-stage validation and risk reduction in clinical development 152
11.2.2 PHASE III 153
11.2.2.1 Regulatory-grade endpoint validation drives high-stakes clinical trial adoption 153

11.2.3 PHASE IV 154
11.2.3.1 Real-world evidence demand drives scalable continuous monitoring and reimbursement adoption 154
11.3 CLINICAL CARE 155
11.3.1 RISING CHRONIC DISEASE BURDEN DRIVING SHIFT TO CONTINUOUS PROACTIVE CARE 155

12 DIGITAL BIOMARKER MARKET, BY END USER 157

12.1 INTRODUCTION 158
12.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 158
12.2.1 CLINICAL TRIAL DRIVEN EFFICIENCY THROUGH HIGH-IMPACT DIGITAL ENDPOINTS 158
12.3 CONTRACT RESEARCH ORGANIZATIONS 159
12.3.1 END-TO-END DIGITAL TRIAL EXECUTION ENABLED THROUGH ADVANCED ANALYTICS 159
12.4 HOSPITALS & SPECIALTY CLINICS 160
12.4.1 ENHANCED CLINICAL OUTCOMES WITH REAL-TIME, DATA-DRIVEN CARE DELIVERY 160
12.5 OTHER END USERS 161
12.5.1 PUBLIC FUNDING AND REAL-WORLD DATA INITIATIVES ACCELERATE ECOSYSTEM-WIDE ADOPTION 161

13 DIGITAL BIOMARKERS MARKET, BY REGION 163

13.1 INTRODUCTION 164
13.2 NORTH AMERICA 164
13.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 165
13.2.2 US 170
13.2.2.1 Regulatory advancements and pharma-tech convergence drive market growth 170
13.2.3 CANADA 174
13.2.3.1 Increasing integration of AI-driven screening and remote monitoring to drive market 174
13.3 EUROPE 178
13.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 179
13.3.2 GERMANY 183
13.3.2.1 Strong clinical trial ecosystem and progressive digital health regulation to drive market 183
13.3.3 FRANCE 187
13.3.3.1 Strong clinical trial base and evidence-driven regulatory pathways to drive market 187
13.3.4 UK 191
13.3.4.1 Strong NHS data infrastructure and push for data-enabled clinical trials to drive market 191
13.3.5 ITALY 195
13.3.5.1 Strong clinical research activity and oncology-driven demand to shape market growth 195
13.3.6 SPAIN 199
13.3.6.1 Strong clinical trial leadership and high domestic research concentration to drive market 199
13.3.7 REST OF EUROPE 203
13.4 LATIN AMERICA 208
13.4.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 208
13.4.2 BRAZIL 212
13.4.2.1 Expanding digital health ecosystem and regulatory reforms to drive digital biomarkers adoption 212
13.4.3 MEXICO 216
13.4.3.1 Growing clinical trial participation and digital transformation to drive digital biomarkers adoption 216
13.4.4 REST OF LATIN AMERICA 220
13.5 ASIA PACIFIC 224
13.5.1 ASIA PACIFIC: CLINICAL TRIAL INITIATIONS IN 2014 AND 2024 225
13.5.2 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 225
13.5.3 CHINA 230
13.5.3.1 Expanding clinical trial leadership and advancing digital health ecosystem to drive market 230
13.5.4 JAPAN 234
13.5.4.1 Declining clinical trial activity despite strong legacy position to impact market 234
13.5.5 INDIA 238
13.5.5.1 Rapid clinical trial growth, cost advantages, and regulatory reforms to drive market 238
13.5.6 AUSTRALIA 242
13.5.6.1 Strong early-phase trial capabilities and advanced research infrastructure to drive market 242
13.5.7 SOUTH KOREA 246
13.5.7.1 Steady clinical trial growth and strong innovation ecosystem to drive market 246
13.5.8 REST OF ASIA PACIFIC 250
13.6 MIDDLE EAST & AFRICA 255
13.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 255
13.6.2 GCC COUNTRIES 260
13.6.2.1 Strong digital health transformation and growing clinical research activity to drive adoption 260
13.6.3 SAUDI ARABIA 264
13.6.3.1 Expanding clinical research activity and government-led initiatives to drive market 264
13.6.4 UAE 268
13.6.4.1 Advancing digital health innovation and strategic collaborations – key growth drivers 268
13.6.5 OTHER GCC COUNTRIES 272
13.6.5.1 Regulatory initiatives, national health visions, and digital health infrastructure boost market growth 272
13.6.6 SOUTH AFRICA 276
13.6.6.1 Leading clinical research hub in Africa with strong infrastructure 276
13.6.7 REST OF MIDDLE EAST & AFRICA 280

14 COMPETITIVE LANDSCAPE 285

14.1 OVERVIEW 285
14.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 285
14.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN DIGITAL BIOMARKERS MARKET 286
14.3 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS 288
14.4 MARKET SHARE ANALYSIS, 2025 289
14.5 BRAND COMPARISON 292
14.6 COMPANY VALUATION & FINANCIAL METRICS 293
14.6.1 FINANCIAL METRICS 293
14.6.2 COMPANY VALUATION 293
14.7 COMPANY EVALUATION MATRIX 294
14.7.1 STARS 294
14.7.2 EMERGING LEADERS 294
14.7.3 PERVASIVE PLAYERS 294
14.7.4 PARTICIPANTS 294
14.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 296
14.7.5.1 Company footprint 296
14.7.5.2 Region footprint 297
14.7.5.3 Type footprint 298
14.7.5.4 Therapeutic area footprint 299
14.7.5.5 Application footprint 300
14.7.5.6 End user footprint 301
14.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 302
14.8.1 PROGRESSIVE COMPANIES 302
14.8.2 RESPONSIVE COMPANIES 302
14.8.3 DYNAMIC COMPANIES 302
14.8.4 STARTING BLOCKS 302
14.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 304
14.8.5.1 Detailed list of key startups/SMEs 304
14.8.5.2 Competitive benchmarking of startups/SMEs 305
14.9 COMPETITIVE SCENARIO 306
14.9.1 PRODUCT/SERVICE LAUNCHES & APPROVALS 306
14.9.2 DEALS 307
14.9.3 OTHER DEVELOPMENTS 308

15 COMPANY PROFILES 309

15.1 KEY PLAYERS 309
15.1.1 IXICO PLC 309
15.1.1.1 Business overview 309
15.1.1.2 Products offered 310
15.1.1.3 Recent developments 311
15.1.1.3.1 Product launches/approvals 311
15.1.1.3.2 Deals 311
15.1.1.4 MnM view 312
15.1.1.4.1 Key strengths 312
15.1.1.4.2 Strategic choices 313
15.1.1.4.3 Weaknesses and competitive threats 313
15.1.2 AMETRIS, LLC 314
15.1.2.1 Business overview 314
15.1.2.2 Products Offered 315
15.1.2.3 Recent developments 315
15.1.2.3.1 Product launches/enhancements 315
15.1.2.3.2 Deals 316
15.1.2.4 MnM view 318
15.1.2.4.1 Key strengths 318
15.1.2.4.2 Strategic choices 318
15.1.2.4.3 Weaknesses and competitive threats 318
15.1.3 EMPATICA INC. 319
15.1.3.1 Business overview 319
15.1.3.2 Products/Solutions offered 320
15.1.3.3 Recent developments 321
15.1.3.3.1 Product launches/approvals 321
15.1.3.3.2 Deals 322
15.1.3.4 MnM view 323
15.1.3.4.1 Key strengths 323
15.1.3.4.2 Strategic choices 323
15.1.3.4.3 Weaknesses and competitive threats 323
15.1.4 ALIVECOR, INC. 324
15.1.4.1 Business overview 324
15.1.4.2 Products offered 325
15.1.4.3 Recent developments 326
15.1.4.3.1 Product launches/approvals 326
15.1.4.3.2 Deals 326
15.1.4.4 MnM view 328
15.1.4.4.1 Key strengths 328
15.1.4.4.2 Strategic choices 328
15.1.4.4.3 Weaknesses and competitive threats 328
15.1.5 CONNEQT HEALTH 329
15.1.5.1 Business overview 329
15.1.5.2 Products offered 331
15.1.5.3 Recent developments 331
15.1.5.3.1 Product enhancements/approvals 331
15.1.5.4 MnM view 332
15.1.5.4.1 Key strengths 332
15.1.5.4.2 Strategic choices 332
15.1.5.4.3 Weaknesses and competitive threats 332
15.1.6 VIVOSENSE 333
15.1.6.1 Business overview 333
15.1.6.2 Products offered 333
15.1.6.2.1 Other developments 334
15.1.7 BIOSENSICS 335
15.1.7.1 Business overview 335
15.1.7.2 Products offered 336
15.1.7.3 Recent developments 336
15.1.7.3.1 Product launches/approvals 336
15.1.7.3.2 Deals 337
15.1.8 LUNIT INC. 338
15.1.8.1 Business overview 338
15.1.8.2 Products offered 340
15.1.8.3 Recent developments 341
15.1.8.3.1 Product launches/approvals 341
15.1.8.3.2 Deals 342
15.1.9 AKILI, INC. 345
15.1.9.1 Business overview 345
15.1.9.2 Products offered 345
15.1.9.3 Recent developments 346
15.1.9.3.1 Deals 346
15.1.10 QUIBIM 347
15.1.10.1 Business overview 347
15.1.10.2 Products offered 347
15.1.10.3 Recent developments 349
15.1.10.3.1 Product launches/approvals/enhancements 349
15.1.10.3.2 Deals 350
15.1.11 CLARIO 351
15.1.11.1 Business overview 351
15.1.11.2 Products offered 352
15.1.11.3 Recent developments 353
15.1.11.3.1 Deals 353

15.1.12 PROSCIA INC. 356
15.1.12.1 Business overview 356
15.1.12.2 Products offered 357
15.1.12.3 Recent developments 358
15.1.12.3.1 Product launches/approvals 358
15.1.12.3.2 Deals 358
15.1.13 KONEKSA HEALTH 361
15.1.13.1 Business overview 361
15.1.13.2 Products offered 362
15.1.13.3 Recent developments 363
15.1.13.3.1 Product launches 363
15.1.13.3.2 Deals 364
15.1.14 LINUS HEALTH 365
15.1.14.1 Business overview 365
15.1.14.2 Products offered 366
15.1.14.3 Recent developments 366
15.1.14.3.1 Product launches/approvals 366
15.1.14.3.2 Deals 367
15.2 OTHER PLAYERS 369
15.2.1 SONDE HEALTH, INC. 369
15.2.2 ALTOIDA 370
15.2.3 IMVARIA INC. 371
15.2.4 CUMULUS NEUROSCIENCE LIMITED 372
15.2.5 DELVE HEALTH 373
15.2.6 FEEL THERAPEUTICS 374
15.2.7 NANOWEAR INC. 375
15.2.8 EXOSYSTEMS 376
15.2.9 CARDIOSIGNAL 377
15.2.10 IMAGENE AI LTD. 378
15.2.11 NEUROTRACK TECHNOLOGIES, INC. 379

16 RESEARCH METHODOLOGY 380

16.1 RESEARCH APPROACH 380
16.1.1 SECONDARY RESEARCH 381
16.1.1.1 Key data from secondary sources 382
16.1.2 PRIMARY RESEARCH 382
16.1.2.1 Primary sources 383
16.1.2.2 Key data from primary sources 384
16.1.2.3 Breakdown of primaries 384
16.1.2.4 Insights from primary experts 385

16.2 RESEARCH METHODOLOGY DESIGN 385
16.3 MARKET SIZE ESTIMATION 386
16.4 MARKET BREAKDOWN DATA TRIANGULATION 391
16.5 MARKET SHARE ESTIMATION 392
16.6 STUDY ASSUMPTIONS 392
16.7 RESEARCH LIMITATIONS 393
16.7.1 METHODOLOGY-RELATED LIMITATIONS 393
16.8 RISK ASSESSMENT 393

17 APPENDIX 394

17.1 DISCUSSION GUIDE 394
17.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 398
17.3 CUSTOMIZATION OPTIONS 400
17.4 RELATED REPORTS 400
17.5 AUTHOR DETAILS 401

LIST OF TABLES

TABLE 1 USD EXCHANGE RATES 39
TABLE 2 DIGITAL BIOMARKERS MARKET: PORTER’S FIVE FORCES ANALYSIS 59
TABLE 3 DIGITAL BIOMARKERS MARKET: ROLE IN ECOSYSTEM 63
TABLE 4 INDICATIVE PRICE FOR DIGITAL BIOMARKERS, BY KEY PLAYER (2025) 64
TABLE 5 INDICATIVE PRICE FOR DIGITAL BIOMARKERS, BY REGION (2025) 65
TABLE 6 CASE 1: EMPATICA – INTEGRATION OF DIGITAL BIOMARKERS INTO HIGH-ALTITUDE ENDOCRINOLOGY RESEARCH (APEX 7 HICORT STUDY) 68
TABLE 7 CASE 2: VIVOSENSE – DIGITAL BIOMARKERS FOR PTSD MONITORING AND ASSESSMENT 69
TABLE 8 CASE 3: DELVE HEALTH – IMPROVED DATA INTEGRITY IN CLINICAL
TRIALS WITH DIGITAL BIOMARKERS 70
TABLE 9 US ADJUSTED RECIPROCAL TARIFF RATES 71
TABLE 10 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF
TOP THREE END USERS (%) 76
TABLE 11 KEY BUYING CRITERIA FOR TOP THREE END USERS 77
TABLE 12 UNMET NEEDS IN DIGITAL BIOMARKERS MARKET 78
TABLE 13 END USER EXPECTATIONS IN DIGITAL BIOMARKERS MARKET 79
TABLE 14 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 81
TABLE 15 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 82
TABLE 16 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 82
TABLE 17 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 83
TABLE 18 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 84
TABLE 19 REGULATORY SCENARIO IN NORTH AMERICA 85
TABLE 20 REGULATORY SCENARIO IN EUROPE 86
TABLE 21 REGULATORY SCENARIO IN ASIA PACIFIC 87
TABLE 22 REGULATORY SCENARIO IN LATIN AMERICA 88
TABLE 23 REGULATORY SCENARIO IN MIDDLE EAST & AFRICA 88
TABLE 24 DIGITAL BIOMARKERS MARKET: JURISDICTION ANALYSIS OF
TOP APPLICANT COUNTRIES 94
TABLE 25 DIGITAL BIOMARKERS MARKET: LIST OF PATENTS/PATENT APPLICATIONS 96
TABLE 26 DIGITAL BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 105
TABLE 27 PHYSIOLOGICAL BIOMARKERS: MAJOR PLAYERS AND OFFERINGS 106
TABLE 28 PHYSIOLOGICAL BIOMARKERS: DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION) 107
TABLE 29 IDIOSYNCRATIC BIOMARKERS: MAJOR PLAYERS AND OFFERINGS 108
TABLE 30 IDIOSYNCRATIC BIOMARKERS: DIGITAL BIOMARKERS MARKET, BY REGION,
2024–2031 (USD MILLION) 108
TABLE 31 COGNITIVE BIOMARKERS: MAJOR PLAYERS AND OFFERINGS 109
TABLE 32 COGNITIVE BIOMARKERS: DIGITAL BIOMARKERS MARKET, BY REGION,
2024–2031 (USD MILLION) 110
TABLE 33 VOCAL BIOMARKERS: MAJOR PLAYERS AND OFFERINGS 111
TABLE 34 VOCAL BIOMARKERS: DIGITAL BIOMARKERS MARKET, BY REGION,
2024–2031 (USD MILLION) 111
TABLE 35 OTHER BIOMARKERS: MAJOR PLAYERS AND OFFERINGS 112
TABLE 36 OTHER BIOMARKERS: DIGITAL BIOMARKERS MARKET, BY REGION,
2024–2031 (USD MILLION) 113
TABLE 37 DIGITAL BIOMARKERS MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 115
TABLE 38 CARDIOVASCULAR: MAJOR PLAYERS AND OFFERINGS 116
TABLE 39 CARDIOVASCULAR: DIGITAL BIOMARKERS MARKET, BY CONDITION,
2024–2031 (USD MILLION) 117
TABLE 40 CARDIOVASCULAR: DIGITAL BIOMARKERS MARKET, BY REGION,
2024–2031 (USD MILLION) 117
TABLE 41 ASCVD/SECONDARY PREVENTION: DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION) 118
TABLE 42 HEART FAILURE (HFREF & HFPEF): DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION) 119
TABLE 43 HYPERTENSION: DIGITAL BIOMARKERS MARKET, BY REGION,
2024–2031 (USD MILLION) 120
TABLE 44 ATRIAL FIBRILLATION/STROKE PREVENTION: DIGITAL BIOMARKERS MARKET,
BY REGION, 2024–2031 (USD MILLION) 120
TABLE 45 PULMONARY HYPERTENSION: DIGITAL BIOMARKERS MARKET, BY REGION,
2024–2031 (USD MILLION) 121
TABLE 46 STRUCTURAL HEART DISEASE/INTERVENTIONAL CARDIOLOGY: DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION) 122
TABLE 47 ONCOLOGY: MAJOR PLAYERS AND OFFERINGS 123
TABLE 48 ONCOLOGY: DIGITAL BIOMARKERS MARKET, BY TUMOR TYPE,
2024–2031 (USD MILLION) 124
TABLE 49 ONCOLOGY: DIGITAL BIOMARKERS MARKET, BY REGION,
2024–2031 (USD MILLION) 124
TABLE 50 SOLID TUMORS: DIGITAL BIOMARKERS MARKET, BY TYPE,
2024–2031 (USD MILLION) 125
TABLE 51 SOLID TUMORS: DIGITAL BIOMARKERS MARKET, BY REGION,
2024–2031 (USD MILLION) 125
TABLE 52 BREAST CANCER: DIGITAL BIOMARKERS MARKET, BY REGION,
2024–2031 (USD MILLION) 126
TABLE 53 LUNG CANCER: DIGITAL BIOMARKERS MARKET, BY REGION,
2024–2031 (USD MILLION) 126
TABLE 54 PROSTATE CANCER: DIGITAL BIOMARKERS MARKET, BY REGION,
2024–2031 (USD MILLION) 127
TABLE 55 COLORECTAL CANCER: DIGITAL BIOMARKERS MARKET, BY REGION,
2024–2031 (USD MILLION) 128
TABLE 56 BRAIN TUMOR: DIGITAL BIOMARKERS MARKET, BY REGION,
2024–2031 (USD MILLION) 129
TABLE 57 OTHER SOLID TUMORS: DIGITAL BIOMARKERS MARKET, BY REGION,
2024–2031 (USD MILLION) 130
TABLE 58 HEMATOLOGIC MALIGNANCIES: DIGITAL BIOMARKERS MARKET, BY TYPE,
2024–2031 (USD MILLION) 130
TABLE 59 HEMATOLOGIC MALIGNANCIES: DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION) 131
TABLE 60 LEUKEMIA: DIGITAL BIOMARKERS MARKET, BY REGION,
2024–2031 (USD MILLION) 132
TABLE 61 LYMPHOMA: DIGITAL BIOMARKERS MARKET, BY REGION,
2024–2031 (USD MILLION) 133
TABLE 62 MULTIPLE MYELOMA: DIGITAL BIOMARKERS MARKET, BY REGION,
2024–2031 (USD MILLION) 134
TABLE 63 OTHER HEMATOLOGIC MALIGNANCIES: DIGITAL BIOMARKERS MARKET,
BY REGION, 2024–2031 (USD MILLION) 135
TABLE 64 DIABETES: MAJOR PLAYERS AND OFFERINGS 136
TABLE 65 DIABETES: DIGITAL BIOMARKERS MARKET, BY REGION,
2024–2031 (USD MILLION) 136
TABLE 66 MENTAL HEALTH & BEHAVIORAL HEALTH: MAJOR PLAYERS AND OFFERINGS 138
TABLE 67 MENTAL HEALTH & BEHAVIORAL HEALTH: DIGITAL BIOMARKERS MARKET,
BY REGION, 2024–2031 (USD MILLION) 138
TABLE 68 RESPIRATORY DISORDERS: MAJOR PLAYERS AND OFFERINGS 139
TABLE 69 RESPIRATORY DISORDERS: DIGITAL BIOMARKERS MARKET, BY REGION,
2024–2031 (USD MILLION) 140
TABLE 70 LIFESTYLE & WELLNESS IMPROVEMENT: MAJOR PLAYERS AND OFFERINGS 141
TABLE 71 LIFESTYLE & WELLNESS IMPROVEMENT: DIGITAL BIOMARKERS MARKET,
BY REGION, 2024–2031 (USD MILLION) 142
TABLE 72 NEUROLOGY: MAJOR PLAYERS AND OFFERINGS 143
TABLE 73 NEUROLOGY: DIGITAL BIOMARKERS MARKET, BY REGION,
2024–2031 (USD MILLION) 144
TABLE 74 MUSCULOSKELETAL DISORDERS/PAIN MANAGEMENT:
MAJOR PLAYERS AND OFFERINGS 145
TABLE 75 MUSCULOSKELETAL DISORDERS/PAIN MANAGEMENT: DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION) 145
TABLE 76 WOMEN’S HEALTH & REPRODUCTIVE HEALTH: MAJOR PLAYERS AND OFFERINGS 147
TABLE 77 WOMEN’S HEALTH & REPRODUCTIVE HEALTH: DIGITAL BIOMARKERS MARKET,
BY REGION, 2024–2031 (USD MILLION) 147
TABLE 78 OTHER DISEASES: DIGITAL BIOMARKERS MARKET, BY REGION,
2024–2031 (USD MILLION) 148
TABLE 79 DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 150
TABLE 80 CLINICAL RESEARCH: DIGITAL BIOMARKERS MARKET, BY PHASE,
2024–2031 (USD MILLION) 151
TABLE 81 CLINICAL RESEARCH: DIGITAL BIOMARKERS MARKET, BY REGION,
2024–2031 (USD MILLION) 152
TABLE 82 PHASE II CLINICAL RESEARCH: DIGITAL BIOMARKERS MARKET, BY REGION,
2024–2031 (USD MILLION) 153
TABLE 83 PHASE III CLINICAL RESEARCH: DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION) 154
TABLE 84 PHASE IV CLINICAL RESEARCH: DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION) 155
TABLE 85 CLINICAL CARE: DIGITAL BIOMARKERS MARKET, BY REGION,
2024–2031 (USD MILLION) 156
TABLE 86 DIGITAL BIOMARKER MARKET, BY END USER, 2024–2031 (USD MILLION) 158
TABLE 87 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES: DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION) 159
TABLE 88 CONTRACT RESEARCH ORGANIZATIONS: DIGITAL BIOMARKERS MARKET,
BY REGION, 2024–2031 (USD MILLION) 160
TABLE 89 HOSPITALS & SPECIALTY CLINICS: DIGITAL BIOMARKERS MARKET,
BY REGION, 2024–2031 (USD MILLION) 161
TABLE 90 OTHER END USERS: DIGITAL BIOMARKERS MARKET, BY REGION,
2024–2031 (USD MILLION) 162
TABLE 91 DIGITAL BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION) 164
TABLE 92 NORTH AMERICA: DIGITAL BIOMARKERS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 166
TABLE 93 NORTH AMERICA: DIGITAL BIOMARKERS MARKET, BY TYPE,
2024–2031 (USD MILLION) 166
TABLE 94 NORTH AMERICA: DIGITAL BIOMARKERS MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 167
TABLE 95 NORTH AMERICA: DIGITAL BIOMARKERS MARKET FOR CARDIOVASCULAR,
BY CONDITION, 2024–2031 (USD MILLION) 167
TABLE 96 NORTH AMERICA: DIGITAL BIOMARKERS MARKET FOR ONCOLOGY,
BY TUMOR TYPE, 2024–2031 (USD MILLION) 168
TABLE 97 NORTH AMERICA: DIGITAL BIOMARKERS MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION) 168
TABLE 98 NORTH AMERICA: DIGITAL BIOMARKERS MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 168
TABLE 99 NORTH AMERICA: DIGITAL BIOMARKERS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 169
TABLE 100 NORTH AMERICA: DIGITAL BIOMARKERS MARKET FOR CLINICAL RESEARCH,
BY PHASE, 2024–2031 (USD MILLION) 169
TABLE 101 NORTH AMERICA: DIGITAL BIOMARKERS MARKET, BY END USER,
2024–2031 (USD MILLION) 169
TABLE 102 US: DIGITAL BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 171
TABLE 103 US: DIGITAL BIOMARKERS MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 171
TABLE 104 US: DIGITAL BIOMARKERS MARKET FOR CARDIOVASCULAR, BY CONDITION,
2024–2031 (USD MILLION) 172
TABLE 105 US: DIGITAL BIOMARKERS MARKET FOR ONCOLOGY, BY TUMOR TYPE,
2024–2031 (USD MILLION) 172
TABLE 106 US: DIGITAL BIOMARKERS MARKET FOR SOLID TUMORS, BY TYPE,
2024–2031 (USD MILLION) 173
TABLE 107 US: DIGITAL BIOMARKERS MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 173
TABLE 108 US: DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 173
TABLE 109 US: DIGITAL BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY PHASE,
2024–2031 (USD MILLION) 174
TABLE 110 US: DIGITAL BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 174
TABLE 111 CANADA: DIGITAL BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 175
TABLE 112 CANADA: DIGITAL BIOMARKERS MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 175
TABLE 113 CANADA: DIGITAL BIOMARKERS MARKET FOR CARDIOVASCULAR, BY CONDITION, 2024–2031 (USD MILLION) 176
TABLE 114 CANADA: DIGITAL BIOMARKERS MARKET FOR ONCOLOGY, BY TUMOR TYPE,
2024–2031 (USD MILLION) 176
TABLE 115 CANADA: DIGITAL BIOMARKERS MARKET FOR SOLID TUMORS, BY TYPE,
2024–2031 (USD MILLION) 177
TABLE 116 CANADA: DIGITAL BIOMARKERS MARKET FOR HEMATOLOGIC MALIGNANCIES,
BY TYPE, 2024–2031 (USD MILLION) 177
TABLE 117 CANADA: DIGITAL BIOMARKERS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 177
TABLE 118 CANADA: DIGITAL BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY PHASE, 2024–2031 (USD MILLION) 178
TABLE 119 CANADA: DIGITAL BIOMARKERS MARKET, BY END USER,
2024–2031 (USD MILLION) 178
TABLE 120 EUROPE: DIGITAL BIOMARKERS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 179
TABLE 121 EUROPE: DIGITAL BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 180
TABLE 122 EUROPE: DIGITAL BIOMARKERS MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 180
TABLE 123 EUROPE: DIGITAL BIOMARKERS MARKET FOR CARDIOVASCULAR, BY CONDITION, 2024–2031 (USD MILLION) 181
TABLE 124 EUROPE: DIGITAL BIOMARKERS MARKET FOR ONCOLOGY, BY TUMOR TYPE,
2024–2031 (USD MILLION) 181
TABLE 125 EUROPE: DIGITAL BIOMARKERS MARKET FOR SOLID TUMORS, BY TYPE,
2024–2031 (USD MILLION) 182
TABLE 126 EUROPE: DIGITAL BIOMARKERS MARKET FOR HEMATOLOGIC MALIGNANCIES,
BY TYPE, 2024–2031 (USD MILLION) 182
TABLE 127 EUROPE: DIGITAL BIOMARKERS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 182
TABLE 128 EUROPE: DIGITAL BIOMARKERS MARKET FOR CLINICAL RESEARCH,
BY PHASE, 2024–2031 (USD MILLION) 183
TABLE 129 EUROPE: DIGITAL BIOMARKERS MARKET, BY END USER,
2024–2031 (USD MILLION) 183
TABLE 130 GERMANY: DIGITAL BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 184
TABLE 131 GERMANY: DIGITAL BIOMARKERS MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 184
TABLE 132 GERMANY: DIGITAL BIOMARKERS MARKET FOR CARDIOVASCULAR, BY CONDITION, 2024–2031 (USD MILLION) 185
TABLE 133 GERMANY: DIGITAL BIOMARKERS MARKET FOR ONCOLOGY, BY TUMOR TYPE, 2024–2031 (USD MILLION) 185
TABLE 134 GERMANY: DIGITAL BIOMARKERS MARKET FOR SOLID TUMORS, BY TYPE,
2024–2031 (USD MILLION) 186
TABLE 135 GERMANY: DIGITAL BIOMARKERS MARKET FOR HEMATOLOGIC MALIGNANCIES,
BY TYPE, 2024–2031 (USD MILLION) 186
TABLE 136 GERMANY: DIGITAL BIOMARKERS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 186
TABLE 137 GERMANY: DIGITAL BIOMARKERS MARKET FOR CLINICAL RESEARCH,
BY PHASE, 2024–2031 (USD MILLION) 187
TABLE 138 GERMANY: DIGITAL BIOMARKERS MARKET, BY END USER,
2024–2031 (USD MILLION) 187
TABLE 139 FRANCE: DIGITAL BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 188
TABLE 140 FRANCE: DIGITAL BIOMARKERS MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 188
TABLE 141 FRANCE: DIGITAL BIOMARKERS MARKET FOR CARDIOVASCULAR, BY CONDITION, 2024–2031 (USD MILLION) 189
TABLE 142 FRANCE: DIGITAL BIOMARKERS MARKET FOR ONCOLOGY, BY TUMOR TYPE,
2024–2031 (USD MILLION) 189
TABLE 143 FRANCE: DIGITAL BIOMARKERS MARKET FOR SOLID TUMORS, BY TYPE,
2024–2031 (USD MILLION) 190
TABLE 144 FRANCE: DIGITAL BIOMARKERS MARKET FOR HEMATOLOGIC MALIGNANCIES,
BY TYPE, 2024–2031 (USD MILLION) 190
TABLE 145 FRANCE: DIGITAL BIOMARKERS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 190
TABLE 146 FRANCE: DIGITAL BIOMARKERS MARKET FOR CLINICAL RESEARCH,
BY PHASE, 2024–2031 (USD MILLION) 191
TABLE 147 FRANCE: DIGITAL BIOMARKERS MARKET, BY END USER,
2024–2031 (USD MILLION) 191
TABLE 148 UK: DIGITAL BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 192
TABLE 149 UK: DIGITAL BIOMARKERS MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 192
TABLE 150 UK: DIGITAL BIOMARKERS MARKET FOR CARDIOVASCULAR, BY CONDITION,
2024–2031 (USD MILLION) 193
TABLE 151 UK: DIGITAL BIOMARKERS MARKET FOR ONCOLOGY, BY TUMOR TYPE,
2024–2031 (USD MILLION) 193
TABLE 152 UK: DIGITAL BIOMARKERS MARKET FOR SOLID TUMORS, BY TYPE,
2024–2031 (USD MILLION) 194
TABLE 153 UK: DIGITAL BIOMARKERS MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 194
TABLE 154 UK: DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 194
TABLE 155 UK: DIGITAL BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY PHASE,
2024–2031 (USD MILLION) 195
TABLE 156 UK: DIGITAL BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 195
TABLE 157 ITALY: DIGITAL BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 196
TABLE 158 ITALY: DIGITAL BIOMARKERS MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 196
TABLE 159 ITALY: DIGITAL BIOMARKERS MARKET FOR CARDIOVASCULAR, BY CONDITION, 2024–2031 (USD MILLION) 197
TABLE 160 ITALY: DIGITAL BIOMARKERS MARKET FOR ONCOLOGY, BY TUMOR TYPE,
2024–2031 (USD MILLION) 197
TABLE 161 ITALY: DIGITAL BIOMARKERS MARKET FOR SOLID TUMORS, BY TYPE,
2024–2031 (USD MILLION) 198
TABLE 162 ITALY: DIGITAL BIOMARKERS MARKET FOR HEMATOLOGIC MALIGNANCIES,
BY TYPE, 2024–2031 (USD MILLION) 198
TABLE 163 ITALY: DIGITAL BIOMARKERS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 198
TABLE 164 ITALY: DIGITAL BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY PHASE, 2024–2031 (USD MILLION) 199
TABLE 165 ITALY: DIGITAL BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 199
TABLE 166 SPAIN: DIGITAL BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 200
TABLE 167 SPAIN: DIGITAL BIOMARKERS MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 200
TABLE 168 SPAIN: DIGITAL BIOMARKERS MARKET FOR CARDIOVASCULAR,
BY CONDITION, 2024–2031 (USD MILLION) 201
TABLE 169 SPAIN: DIGITAL BIOMARKERS MARKET FOR ONCOLOGY, BY TUMOR TYPE,
2024–2031 (USD MILLION) 201
TABLE 170 SPAIN: DIGITAL BIOMARKERS MARKET FOR SOLID TUMORS, BY TYPE,
2024–2031 (USD MILLION) 202
TABLE 171 SPAIN: DIGITAL BIOMARKERS MARKET FOR HEMATOLOGIC MALIGNANCIES,
BY TYPE, 2024–2031 (USD MILLION) 202
TABLE 172 SPAIN: DIGITAL BIOMARKERS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 202
TABLE 173 SPAIN: DIGITAL BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY PHASE, 2024–2031 (USD MILLION) 203
TABLE 174 SPAIN: DIGITAL BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 203
TABLE 175 REST OF EUROPE: DIGITAL BIOMARKERS MARKET, BY TYPE,
2024–2031 (USD MILLION) 204
TABLE 176 REST OF EUROPE: DIGITAL BIOMARKERS MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 205
TABLE 177 REST OF EUROPE: DIGITAL BIOMARKERS MARKET FOR CARDIOVASCULAR,
BY CONDITION, 2024–2031 (USD MILLION) 205
TABLE 178 REST OF EUROPE: DIGITAL BIOMARKERS MARKET FOR ONCOLOGY, BY TUMOR TYPE, 2024–2031 (USD MILLION) 206
TABLE 179 REST OF EUROPE: DIGITAL BIOMARKERS MARKET FOR SOLID TUMORS,
BY TYPE, 2024–2031 (USD MILLION) 206
TABLE 180 REST OF EUROPE: DIGITAL BIOMARKERS MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 206
TABLE 181 REST OF EUROPE: DIGITAL BIOMARKERS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 207
TABLE 182 REST OF EUROPE: DIGITAL BIOMARKERS MARKET FOR CLINICAL RESEARCH,
BY PHASE, 2024–2031 (USD MILLION) 207
TABLE 183 REST OF EUROPE: DIGITAL BIOMARKERS MARKET, BY END USER,
2024–2031 (USD MILLION) 207
TABLE 184 LATIN AMERICA: DIGITAL BIOMARKERS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 208
TABLE 185 LATIN AMERICA: DIGITAL BIOMARKERS MARKET, BY TYPE,
2024–2031 (USD MILLION) 209
TABLE 186 LATIN AMERICA: DIGITAL BIOMARKERS MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 209
TABLE 187 LATIN AMERICA: DIGITAL BIOMARKERS MARKET FOR CARDIOVASCULAR,
BY CONDITION, 2024–2031 (USD MILLION) 210
TABLE 188 LATIN AMERICA: DIGITAL BIOMARKERS MARKET FOR ONCOLOGY,
BY TUMOR TYPE, 2024–2031 (USD MILLION) 210
TABLE 189 LATIN AMERICA: DIGITAL BIOMARKERS MARKET FOR SOLID TUMORS,
BY TYPE, 2024–2031 (USD MILLION) 211
TABLE 190 LATIN AMERICA: DIGITAL BIOMARKERS MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 211
TABLE 191 LATIN AMERICA: DIGITAL BIOMARKERS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 211
TABLE 192 LATIN AMERICA: DIGITAL BIOMARKERS MARKET FOR CLINICAL RESEARCH,
BY PHASE, 2024–2031 (USD MILLION) 212
TABLE 193 LATIN AMERICA: DIGITAL BIOMARKERS MARKET, BY END USER,
2024–2031 (USD MILLION) 212
TABLE 194 BRAZIL: DIGITAL BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 213
TABLE 195 BRAZIL: DIGITAL BIOMARKERS MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 213
TABLE 196 BRAZIL: DIGITAL BIOMARKERS MARKET FOR CARDIOVASCULAR,
BY CONDITION, 2024–2031 (USD MILLION) 214
TABLE 197 BRAZIL: DIGITAL BIOMARKERS MARKET FOR ONCOLOGY, BY TUMOR TYPE,
2024–2031 (USD MILLION) 214
TABLE 198 BRAZIL: DIGITAL BIOMARKERS MARKET FOR SOLID TUMORS, BY TYPE,
2024–2031 (USD MILLION) 215
TABLE 199 BRAZIL: DIGITAL BIOMARKERS MARKET FOR HEMATOLOGIC MALIGNANCIES,
BY TYPE, 2024–2031 (USD MILLION) 215
TABLE 200 BRAZIL: DIGITAL BIOMARKERS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 215
TABLE 201 BRAZIL: DIGITAL BIOMARKERS MARKET FOR CLINICAL RESEARCH,
BY PHASE, 2024–2031 (USD MILLION) 216
TABLE 202 BRAZIL: DIGITAL BIOMARKERS MARKET, BY END USER,
2024–2031 (USD MILLION) 216
TABLE 203 MEXICO: DIGITAL BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 217
TABLE 204 MEXICO: DIGITAL BIOMARKERS MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 217
TABLE 205 MEXICO: DIGITAL BIOMARKERS MARKET FOR CARDIOVASCULAR, BY CONDITION, 2024–2031 (USD MILLION) 218
TABLE 206 MEXICO: DIGITAL BIOMARKERS MARKET FOR ONCOLOGY, BY TUMOR TYPE,
2024–2031 (USD MILLION) 218
TABLE 207 MEXICO: DIGITAL BIOMARKERS MARKET FOR SOLID TUMORS, BY TYPE,
2024–2031 (USD MILLION) 219
TABLE 208 MEXICO: DIGITAL BIOMARKERS MARKET FOR HEMATOLOGIC MALIGNANCIES,
BY TYPE, 2024–2031 (USD MILLION) 219
TABLE 209 MEXICO: DIGITAL BIOMARKERS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 219
TABLE 210 MEXICO: DIGITAL BIOMARKERS MARKET FOR CLINICAL RESEARCH,
BY PHASE, 2024–2031 (USD MILLION) 220
TABLE 211 MEXICO: DIGITAL BIOMARKERS MARKET, BY END USER,
2024–2031 (USD MILLION) 220
TABLE 212 REST OF LATIN AMERICA: DIGITAL BIOMARKERS MARKET, BY TYPE,
2024–2031 (USD MILLION) 221
TABLE 213 REST OF LATIN AMERICA: DIGITAL BIOMARKERS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 221
TABLE 214 REST OF LATIN AMERICA: DIGITAL BIOMARKERS MARKET FOR CARDIOVASCULAR, BY CONDITION, 2024–2031 (USD MILLION) 222
TABLE 215 REST OF LATIN AMERICA: DIGITAL BIOMARKERS MARKET FOR ONCOLOGY,
BY TUMOR TYPE, 2024–2031 (USD MILLION) 222
TABLE 216 REST OF LATIN AMERICA: DIGITAL BIOMARKERS MARKET FOR SOLID TUMORS,
BY TYPE, 2024–2031 (USD MILLION) 223
TABLE 217 REST OF LATIN AMERICA: DIGITAL BIOMARKERS MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 223
TABLE 218 REST OF LATIN AMERICA: DIGITAL BIOMARKERS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 223
TABLE 219 REST OF LATIN AMERICA: DIGITAL BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY PHASE, 2024–2031 (USD MILLION) 224
TABLE 220 REST OF LATIN AMERICA: DIGITAL BIOMARKERS MARKET, BY END USER,
2024–2031 (USD MILLION) 224
TABLE 221 ASIA PACIFIC: DIGITAL BIOMARKERS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 226
TABLE 222 ASIA PACIFIC: DIGITAL BIOMARKERS MARKET, BY TYPE,
2024–2031 (USD MILLION) 227
TABLE 223 ASIA PACIFIC: DIGITAL BIOMARKERS MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 227
TABLE 224 ASIA PACIFIC: DIGITAL BIOMARKERS MARKET, FOR CARDIOVASCULAR,
BY CONDITION, 2024–2031 (USD MILLION) 228
TABLE 225 ASIA PACIFIC: DIGITAL BIOMARKERS MARKET FOR ONCOLOGY,
BY TUMOR TYPE, 2024–2031 (USD MILLION) 228
TABLE 226 ASIA PACIFIC: DIGITAL BIOMARKERS MARKET FOR SOLID TUMORS,
BY TYPE, 2024–2031 (USD MILLION) 229
TABLE 227 ASIA PACIFIC: DIGITAL BIOMARKERS MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 229
TABLE 228 ASIA PACIFIC: DIGITAL BIOMARKERS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 229
TABLE 229 ASIA PACIFIC: DIGITAL BIOMARKERS MARKET FOR CLINICAL RESEARCH,
BY PHASE, 2024–2031 (USD MILLION) 230
TABLE 230 ASIA PACIFIC: DIGITAL BIOMARKERS MARKET, BY END USER,
2024–2031 (USD MILLION) 230
TABLE 231 CHINA: DIGITAL BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 231
TABLE 232 CHINA: DIGITAL BIOMARKERS MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 231
TABLE 233 CHINA: DIGITAL BIOMARKERS MARKET FOR CARDIOVASCULAR, BY CONDITION, 2024–2031 (USD MILLION) 232
TABLE 234 CHINA: DIGITAL BIOMARKERS MARKET FOR ONCOLOGY, BY TUMOR TYPE,
2024–2031 (USD MILLION) 232
TABLE 235 CHINA: DIGITAL BIOMARKERS MARKET FOR SOLID TUMORS, BY TYPE,
2024–2031 (USD MILLION) 233
TABLE 236 CHINA: DIGITAL BIOMARKERS MARKET FOR HEMATOLOGIC MALIGNANCIES,
BY TYPE, 2024–2031 (USD MILLION) 233
TABLE 237 CHINA: DIGITAL BIOMARKERS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 233
TABLE 238 CHINA: DIGITAL BIOMARKERS MARKET FOR CLINICAL RESEARCH,
BY TYPE, 2024–2031 (USD MILLION) 234
TABLE 239 CHINA: DIGITAL BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 234
TABLE 240 JAPAN: DIGITAL BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 235
TABLE 241 JAPAN: DIGITAL BIOMARKERS MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 235
TABLE 242 JAPAN: DIGITAL BIOMARKERS MARKET FOR CARDIOVASCULAR, BY CONDITION, 2024–2031 (USD MILLION) 236
TABLE 243 JAPAN: DIGITAL BIOMARKERS MARKET FOR ONCOLOGY, BY TUMOR TYPE,
2024–2031 (USD MILLION) 236
TABLE 244 JAPAN: DIGITAL BIOMARKERS MARKET FOR SOLID TUMORS, BY TYPE,
2024–2031 (USD MILLION) 237
TABLE 245 JAPAN: DIGITAL BIOMARKERS MARKET FOR HEMATOLOGIC MALIGNANCIES,
BY TYPE, 2024–2031 (USD MILLION) 237
TABLE 246 JAPAN: DIGITAL BIOMARKERS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 237
TABLE 247 JAPAN: DIGITAL BIOMARKERS MARKET FOR CLINICAL RESEARCH,
BY PHASE, 2024–2031 (USD MILLION) 238
TABLE 248 JAPAN: DIGITAL BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 238
TABLE 249 INDIA: DIGITAL BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 239
TABLE 250 INDIA: DIGITAL BIOMARKERS MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 239
TABLE 251 INDIA: DIGITAL BIOMARKERS MARKET FOR CARDIOVASCULAR,
BY CONDITION, 2024–2031 (USD MILLION) 240
TABLE 252 INDIA: DIGITAL BIOMARKERS MARKET FOR ONCOLOGY, BY TUMOR TYPE,
2024–2031 (USD MILLION) 240
TABLE 253 INDIA: DIGITAL BIOMARKERS MARKET FOR SOLID TUMORS, BY TYPE,
2024–2031 (USD MILLION) 241
TABLE 254 INDIA: DIGITAL BIOMARKERS MARKET FOR HEMATOLOGIC MALIGNANCIES,
BY TYPE, 2024–2031 (USD MILLION) 241
TABLE 255 INDIA: DIGITAL BIOMARKERS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 241
TABLE 256 INDIA: DIGITAL BIOMARKERS MARKET FOR CLINICAL RESEARCH,
BY PHASE, 2024–2031 (USD MILLION) 242
TABLE 257 INDIA: DIGITAL BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 242
TABLE 258 AUSTRALIA: DIGITAL BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 243
TABLE 259 AUSTRALIA: DIGITAL BIOMARKERS MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 243
TABLE 260 AUSTRALIA: DIGITAL BIOMARKERS MARKET FOR CARDIOVASCULAR,
BY CONDITION, 2024–2031 (USD MILLION) 244
TABLE 261 AUSTRALIA: DIGITAL BIOMARKERS MARKET FOR ONCOLOGY, BY TUMOR TYPE, 2024–2031 (USD MILLION) 244
TABLE 262 AUSTRALIA: DIGITAL BIOMARKERS MARKET FOR SOLID TUMORS, BY TYPE,
2024–2031 (USD MILLION) 245
TABLE 263 AUSTRALIA: DIGITAL BIOMARKERS MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 245
TABLE 264 AUSTRALIA: DIGITAL BIOMARKERS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 245
TABLE 265 AUSTRALIA: DIGITAL BIOMARKERS MARKET FOR CLINICAL RESEARCH,
BY TYPE, 2024–2031 (USD MILLION) 246
TABLE 266 AUSTRALIA: DIGITAL BIOMARKERS MARKET, BY END USER,
2024–2031 (USD MILLION) 246
TABLE 267 SOUTH KOREA: DIGITAL BIOMARKERS MARKET, BY TYPE,
2024–2031 (USD MILLION) 247
TABLE 268 SOUTH KOREA: DIGITAL BIOMARKERS MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 247
TABLE 269 SOUTH KOREA: DIGITAL BIOMARKERS MARKET FOR CARDIOVASCULAR,
BY CONDITION, 2024–2031 (USD MILLION) 248
TABLE 270 SOUTH KOREA: DIGITAL BIOMARKERS MARKET FOR ONCOLOGY,
BY TUMOR TYPE, 2024–2031 (USD MILLION) 248
TABLE 271 SOUTH KOREA: DIGITAL BIOMARKERS MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION) 249
TABLE 272 SOUTH KOREA: DIGITAL BIOMARKERS MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 249
TABLE 273 SOUTH KOREA: DIGITAL BIOMARKERS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 249
TABLE 274 SOUTH KOREA: DIGITAL BIOMARKERS MARKET FOR CLINICAL RESEARCH,
BY PHASE, 2024–2031 (USD MILLION) 250
TABLE 275 SOUTH KOREA: DIGITAL BIOMARKERS MARKET, BY END USER,
2024–2031 (USD MILLION) 250
TABLE 276 REST OF ASIA PACIFIC: DIGITAL BIOMARKERS MARKET, BY TYPE,
2024–2031 (USD MILLION) 251
TABLE 277 REST OF ASIA PACIFIC: DIGITAL BIOMARKERS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 252
TABLE 278 REST OF ASIA PACIFIC: DIGITAL BIOMARKERS MARKET FOR CARDIOVASCULAR,
BY CONDITION, 2024–2031 (USD MILLION) 252
TABLE 279 REST OF ASIA PACIFIC: DIGITAL BIOMARKERS MARKET FOR ONCOLOGY,
BY TUMOR TYPE, 2024–2031 (USD MILLION) 253
TABLE 280 REST OF ASIA PACIFIC: DIGITAL BIOMARKERS MARKET FOR SOLID TUMORS,
BY TYPE, 2024–2031 (USD MILLION) 253
TABLE 281 REST OF ASIA PACIFIC: DIGITAL BIOMARKERS MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 253
TABLE 282 REST OF ASIA PACIFIC: DIGITAL BIOMARKERS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 254
TABLE 283 REST OF ASIA PACIFIC: DIGITAL BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY PHASE, 2024–2031 (USD MILLION) 254
TABLE 284 REST OF ASIA PACIFIC: DIGITAL BIOMARKERS MARKET, BY END USER,
2024–2031 (USD MILLION) 254
TABLE 285 MIDDLE EAST & AFRICA: DIGITAL BIOMARKERS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 256
TABLE 286 MIDDLE EAST & AFRICA: DIGITAL BIOMARKERS MARKET, BY TYPE,
2024–2031 (USD MILLION) 256
TABLE 287 MIDDLE EAST & AFRICA: DIGITAL BIOMARKERS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 257
TABLE 288 MIDDLE EAST & AFRICA: DIGITAL BIOMARKERS MARKET FOR CARDIOVASCULAR, BY CONDITION, 2024–2031 (USD MILLION) 257
TABLE 289 MIDDLE EAST & AFRICA: DIGITAL BIOMARKERS MARKET FOR ONCOLOGY,
BY TUMOR TYPE, 2024–2031 (USD MILLION) 258
TABLE 290 MIDDLE EAST & AFRICA: DIGITAL BIOMARKERS MARKET FOR SOLID TUMORS,
BY TYPE, 2024–2031 (USD MILLION) 258
TABLE 291 MIDDLE EAST & AFRICA: DIGITAL BIOMARKERS MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 258
TABLE 292 MIDDLE EAST & AFRICA: DIGITAL BIOMARKERS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 259
TABLE 293 MIDDLE EAST & AFRICA: DIGITAL BIOMARKERS MARKET FOR
CLINICAL RESEARCH, BY PHASE, 2024–2031 (USD MILLION) 259
TABLE 294 MIDDLE EAST & AFRICA: DIGITAL BIOMARKERS MARKET,
BY END USER, 2024–2031 (USD MILLION) 259
TABLE 295 GCC COUNTRIES: DIGITAL BIOMARKERS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 260
TABLE 296 GCC COUNTRIES: DIGITAL BIOMARKERS MARKET, BY TYPE,
2024–2031 (USD MILLION) 261
TABLE 297 GCC COUNTRIES: DIGITAL BIOMARKERS MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 261
TABLE 298 GCC COUNTRIES: DIGITAL BIOMARKERS MARKET FOR CARDIOVASCULAR,
BY CONDITION, 2024–2031 (USD MILLION) 262
TABLE 299 GCC COUNTRIES: DIGITAL BIOMARKERS MARKET FOR ONCOLOGY, BY TUMOR TYPE, 2024–2031 (USD MILLION) 262
TABLE 300 GCC COUNTRIES: DIGITAL BIOMARKERS MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION) 263
TABLE 301 GCC COUNTRIES: DIGITAL BIOMARKERS MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 263
TABLE 302 GCC COUNTRIES: DIGITAL BIOMARKERS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 263
TABLE 303 GCC COUNTRIES: DIGITAL BIOMARKERS MARKET FOR CLINICAL RESEARCH,
BY PHASE, 2024–2031 (USD MILLION) 264
TABLE 304 GCC COUNTRIES: DIGITAL BIOMARKERS MARKET, BY END USER,
2024–2031 (USD MILLION) 264
TABLE 305 SAUDI ARABIA: DIGITAL BIOMARKERS MARKET, BY TYPE,
2024–2031 (USD MILLION) 265
TABLE 306 SAUDI ARABIA: DIGITAL BIOMARKERS MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 265
TABLE 307 SAUDI ARABIA: DIGITAL BIOMARKERS MARKET FOR CARDIOVASCULAR,
BY CONDITION, 2024–2031 (USD MILLION) 266
TABLE 308 SAUDI ARABIA: DIGITAL BIOMARKERS MARKET FOR ONCOLOGY,
BY TUMOR TYPE, 2024–2031 (USD MILLION) 266
TABLE 309 SAUDI ARABIA: DIGITAL BIOMARKERS MARKET FOR SOLID TUMORS,
BY TYPE, 2024–2031 (USD MILLION) 267
TABLE 310 SAUDI ARABIA: DIGITAL BIOMARKERS MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 267
TABLE 311 SAUDI ARABIA: DIGITAL BIOMARKERS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 267
TABLE 312 SAUDI ARABIA: DIGITAL BIOMARKERS MARKET FOR CLINICAL RESEARCH,
BY PHASE, 2024–2031 (USD MILLION) 268
TABLE 313 SAUDI ARABIA: DIGITAL BIOMARKERS MARKET, BY END USER,
2024–2031 (USD MILLION) 268
TABLE 314 UAE: DIGITAL BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 269
TABLE 315 UAE: DIGITAL BIOMARKERS MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 269
TABLE 316 UAE: DIGITAL BIOMARKERS MARKET FOR CARDIOVASCULAR, BY CONDITION, 2024–2031 (USD MILLION) 270
TABLE 317 UAE: DIGITAL BIOMARKERS MARKET FOR ONCOLOGY, BY TUMOR TYPE,
2024–2031 (USD MILLION) 270
TABLE 318 UAE: DIGITAL BIOMARKERS MARKET FOR SOLID TUMORS, BY TYPE,
2024–2031 (USD MILLION) 271
TABLE 319 UAE: DIGITAL BIOMARKERS MARKET FOR HEMATOLOGIC MALIGNANCIES,
BY TYPE, 2024–2031 (USD MILLION) 271
TABLE 320 UAE: DIGITAL BIOMARKERS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 271
TABLE 321 UAE: DIGITAL BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY PHASE,
2024–2031 (USD MILLION) 272
TABLE 322 UAE: DIGITAL BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 272
TABLE 323 OTHER GCC COUNTRIES: DIGITAL BIOMARKERS MARKET, BY TYPE,
2024–2031 (USD MILLION) 273
TABLE 324 OTHER GCC COUNTRIES: DIGITAL BIOMARKERS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 273
TABLE 325 OTHER GCC COUNTRIES: DIGITAL BIOMARKERS MARKET FOR CARDIOVASCULAR, BY CONDITION, 2024–2031 (USD MILLION) 274
TABLE 326 OTHER GCC COUNTRIES: DIGITAL BIOMARKERS MARKET FOR ONCOLOGY,
BY TUMOR TYPE, 2024–2031 (USD MILLION) 274
TABLE 327 OTHER GCC COUNTRIES: DIGITAL BIOMARKERS MARKET FOR SOLID TUMORS,
BY TYPE, 2024–2031 (USD MILLION) 275
TABLE 328 OTHER GCC COUNTRIES: DIGITAL BIOMARKERS MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 275
TABLE 329 OTHER GCC COUNTRIES: DIGITAL BIOMARKERS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 275
TABLE 330 OTHER GCC COUNTRIES: DIGITAL BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY PHASE, 2024–2031 (USD MILLION) 276
TABLE 331 OTHER GCC COUNTRIES: DIGITAL BIOMARKERS MARKET, BY END USER,
2024–2031 (USD MILLION) 276
TABLE 332 SOUTH AFRICA: DIGITAL BIOMARKERS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 277
TABLE 333 SOUTH AFRICA: DIGITAL BIOMARKERS MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 277
TABLE 334 SOUTH AFRICA: DIGITAL BIOMARKERS MARKET FOR CARDIOVASCULAR,
BY CONDITION, 2024–2031 (USD MILLION) 278
TABLE 335 SOUTH AFRICA: DIGITAL BIOMARKERS MARKET FOR ONCOLOGY,
BY TUMOR TYPE, 2024–2031 (USD MILLION) 278
TABLE 336 SOUTH AFRICA: DIGITAL BIOMARKERS MARKET FOR SOLID TUMORS,
BY TYPE, 2024–2031 (USD MILLION) 279
TABLE 337 SOUTH AFRICA: DIGITAL BIOMARKERS MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 279
TABLE 338 SOUTH AFRICA: DIGITAL BIOMARKERS MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 279
TABLE 339 SOUTH AFRICA: DIGITAL BIOMARKERS MARKET FOR CLINICAL RESEARCH,
BY PHASE, 2024–2031 (USD MILLION) 280
TABLE 340 SOUTH AFRICA: DIGITAL BIOMARKERS MARKET, BY END USER,
2024–2031 (USD MILLION) 280
TABLE 341 REST OF MIDDLE EAST & AFRICA: DIGITAL BIOMARKERS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 281
TABLE 342 REST OF MIDDLE EAST & AFRICA: DIGITAL BIOMARKERS MARKET,
BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 281
TABLE 343 REST OF MIDDLE EAST & AFRICA: DIGITAL BIOMARKERS MARKET FOR CARDIOVASCULAR, BY CONDITION, 2024–2031 (USD MILLION) 282
TABLE 344 REST OF MIDDLE EAST & AFRICA: DIGITAL BIOMARKERS MARKET FOR ONCOLOGY, BY TUMOR TYPE, 2024–2031 (USD MILLION) 282
TABLE 345 REST OF MIDDLE EAST & AFRICA: DIGITAL BIOMARKERS MARKET FOR SOLID TUMORS, BY TYPE, 2024–2031 (USD MILLION) 282
TABLE 346 REST OF MIDDLE EAST & AFRICA: DIGITAL BIOMARKERS MARKET FOR HEMATOLOGIC MALIGNANCIES, BY TYPE, 2024–2031 (USD MILLION) 283
TABLE 347 REST OF MIDDLE EAST & AFRICA: DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 283
TABLE 348 REST OF MIDDLE EAST & AFRICA: DIGITAL BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY PHASE, 2024–2031 (USD MILLION) 283
TABLE 349 REST OF MIDDLE EAST & AFRICA: DIGITAL BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION) 284
TABLE 350 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN DIGITAL BIOMARKERS MARKET, JANUARY 2022–MARCH 2026 286
TABLE 351 DIGITAL BIOMARKERS MARKET: DEGREE OF COMPETITION 290
TABLE 352 DIGITAL BIOMARKERS MARKET: REGION FOOTPRINT (14 COMPANIES) 297
TABLE 353 DIGITAL BIOMARKERS MARKET: TYPE FOOTPRINT (14 COMPANIES) 298
TABLE 354 DIGITAL BIOMARKERS MARKET: THERAPEUTIC AREA FOOTPRINT (14 COMPANIES) 299
TABLE 355 DIGITAL BIOMARKERS MARKET: APPLICATION FOOTPRINT (14 COMPANIES) 300
TABLE 356 DIGITAL BIOMARKERS MARKET: END USER FOOTPRINT (14 COMPANIES) 301
TABLE 357 DIGITAL BIOMARKERS MARKET: DETAILED LIST OF KEY STARTUPS/SMES 304
TABLE 358 DIGITAL BIOMARKERS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES, BY REGION 305
TABLE 359 DIGITAL BIOMARKERS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES, BY TYPE 305
TABLE 360 DIGITAL BIOMARKERS MARKET: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2022–MARCH 2026 306
TABLE 361 DIGITAL BIOMARKERS MARKET: DEALS, JANUARY 2022–MARCH 2026 307
TABLE 362 DIGITAL BIOMARKERS MARKET: OTHER DEVELOPMENTS,
JANUARY 2022–MARCH 2026 308
TABLE 363 IXICO PLC: COMPANY OVERVIEW 309
TABLE 364 IXICO PLC: PRODUCTS OFFERED 310
TABLE 365 IXICO PLC.: PRODUCT LAUNCHES/APPROVALS, JANUARY 2022–MARCH 2026 311
TABLE 366 IXICO PLC.: DEALS, JANUARY 2022–MARCH 2026 311
TABLE 367 AMETRIS, LLC: COMPANY OVERVIEW 314
TABLE 368 AMETRIS LLC: PRODUCTS OFFERED 315
TABLE 369 AMETRIS LLC: PRODUCT LAUNCHES/ENHANCEMENTS,
JANUARY 2022–MARCH 2026 315
TABLE 370 AMETRIS, LLC: DEALS, JANUARY 2022–MARCH 2026 316
TABLE 371 EMPATICA INC.: COMPANY OVERVIEW 319
TABLE 372 EMPATICA INC.: PRODUCTS/SOLUTIONS OFFERED 320
TABLE 373 EMPATICA INC.: PRODUCT LAUNCHES/APPROVALS, JANUARY 2022–MARCH 2026 321
TABLE 374 EMPATICA INC.: DEALS, JANUARY 2022–MARCH 2026 322
TABLE 375 ALIVECOR, INC.: COMPANY OVERVIEW 324
TABLE 376 ALIVECOR, INC.: PRODUCTS OFFERED 325
TABLE 377 ALIVECOR, INC.: PRODUCT LAUNCHES/APPROVALS, JANUARY 2022–MARCH 2026 326
TABLE 378 ALIVECOR, INC.: DEALS, JANUARY 2022–MARCH 2026 326
TABLE 379 CONNEQT HEALTH: COMPANY OVERVIEW 329
TABLE 380 CONNEQT HEALTH: PRODUCTS OFFERED 331
TABLE 381 CONNEQT HEALTH: PRODUCT ENHANCEMENTS/APPROVALS,
JANUARY 2022–MARCH 2026 331
TABLE 382 VIVOSENSE: COMPANY OVERVIEW 333
TABLE 383 VIVOSENSE: PRODUCTS OFFERED 333
TABLE 384 VIVOSENSE: OTHER DEVELOPMENTS, JANUARY 2022–MARCH 2026 334
TABLE 385 BIOSENSICS: COMPANY OVERVIEW 335
TABLE 386 BIOSENSICS: PRODUCTS OFFERED 336
TABLE 387 BIOSENSICS: PRODUCT LAUNCHES/APPROVALS, JANUARY 2022–MARCH 2026 336
TABLE 388 BIOSENSICS: DEALS, JANUARY 2022–MARCH 2026 337
TABLE 389 LUNIT INC.: COMPANY OVERVIEW 338
TABLE 390 LUNIT INC.: PRODUCTS OFFERED 340
TABLE 391 LUNIT INC.: PRODUCT LAUNCHES/APPROVALS, JANUARY 2022–MARCH 2026 341
TABLE 392 LUNIT INC.: DEALS, JANUARY 2022–MARCH 2026 342
TABLE 393 AKILI, INC.: COMPANY OVERVIEW 345
TABLE 394 AKILI, INC.: PRODUCTS OFFERED 345
TABLE 395 AKILI, INC.: DEALS, JANUARY 2022–MARCH 2026 346
TABLE 396 QUIBIM: COMPANY OVERVIEW 347
TABLE 397 QUIBIM: PRODUCTS OFFERED 347
TABLE 398 QUIBIM: PRODUCT LAUNCHES/APPROVALS/ENHANCEMENTS,
JANUARY 2022–MARCH 2026 349
TABLE 399 QUIBIM: DEALS, JANUARY 2022–MARCH 2026 350
TABLE 400 CLARIO: COMPANY OVERVIEW 351
TABLE 401 CLARIO: PRODUCTS OFFERED 352
TABLE 402 CLARIO: DEALS, JANUARY 2022–MARCH 2026 353
TABLE 403 PROSCIA INC.: COMPANY OVERVIEW 356
TABLE 404 PROSCIA INC.: PRODUCTS OFFERED 357
TABLE 405 PROSCIA INC.: PRODUCT LAUNCHES/APPROVALS, JANUARY 2022–MARCH 2026 358
TABLE 406 PROSCIA INC.: DEALS, JANUARY 2022–MARCH 2026 358
TABLE 407 KONEKSA HEALTH: COMPANY OVERVIEW 361
TABLE 408 KONEKSA HEALTH: PRODUCTS OFFERED 362
TABLE 409 KONEKSA HEALTH: PRODUCT LAUNCHES, JANUARY 2022–MARCH 2026 363
TABLE 410 KONEKSA HEALTH: DEALS, JANUARY 2022– MARCH 2026 364
TABLE 411 LINUS HEALTH: COMPANY OVERVIEW 365
TABLE 412 LINUS HEALTH: PRODUCTS OFFERED 366
TABLE 413 LINUS HEALTH: PRODUCT LAUNCHES/APPROVALS, JANUARY 2022–MARCH 2026 366
TABLE 414 LINUS HEALTH: DEALS, JANUARY 2022–MARCH 2026 367
TABLE 415 SONDE HEALTH, INC.: COMPANY OVERVIEW 369
TABLE 416 ALTOIDA: COMPANY OVERVIEW 370
TABLE 417 IMVARIA INC.: COMPANY OVERVIEW 371
TABLE 418 CUMULUS NEUROSCIENCE LIMITED: COMPANY OVERVIEW 372
TABLE 419 DELVE HEALTH: COMPANY OVERVIEW 373
TABLE 420 FEEL THERAPEUTICS: COMPANY OVERVIEW 374
TABLE 421 NANOWEAR INC.: COMPANY OVERVIEW 375
TABLE 422 EXOSYSTEMS: COMPANY OVERVIEW 376
TABLE 423 CARDIOSIGNAL: COMPANY OVERVIEW 377
TABLE 424 IMAGENE AI LTD.: COMPANY OVERVIEW 378
TABLE 425 NEUROTRACK TECHNOLOGIES, INC.: COMPANY OVERVIEW 379
TABLE 426 RISK ASSESSMENT: DIGITAL BIOMARKERS MARKET 393

LIST OF FIGURES

FIGURE 1 DIGITAL BIOMARKERS MARKET SEGMENTATION 36
FIGURE 2 MARKET SCENARIO 42
FIGURE 3 GLOBAL DIGITAL BIOMARKERS MARKET, 2024–2031 42
FIGURE 4 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN
DIGITAL BIOMARKERS MARKET, 2023–2026 43
FIGURE 5 DISRUPTIONS INFLUENCING GROWTH OF DIGITAL BIOMARKERS MARKET 44
FIGURE 6 HIGH-GROWTH SEGMENTS IN DIGITAL BIOMARKERS MARKET, 2026–2031 45
FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN DIGITAL BIOMARKERS MARKET DURING FORECAST PERIOD 46
FIGURE 8 RISING IN CLINICAL TRIAL VOLUMES TO DRIVE GROWTH IN
DIGITAL BIOMARKERS MARKET 47
FIGURE 9 CLINICAL RESEARCH APPLICATIONS ACCOUNTED FOR LARGEST MARKET SHARE IN NORTH AMERICA IN 2025 48
FIGURE 10 INDIA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 48
FIGURE 11 DIGITAL BIOMARKERS MARKET: PORTER’S FIVE FORCES ANALYSIS 58
FIGURE 12 DIGITAL BIOMARKERS MARKET: SUPPLY CHAIN ANALYSIS 62
FIGURE 13 DIGITAL BIOMARKERS MARKET: ECOSYSTEM ANALYSIS 63
FIGURE 14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 67
FIGURE 16 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS 76
FIGURE 17 KEY BUYING CRITERIA FOR TOP THREE END USERS 77
FIGURE 18 DIGITAL BIOMARKERS MARKET: PATENT PUBLICATION TRENDS, 2015–2026 93
FIGURE 19 DIGITAL BIOMARKERS MARKET: JURISDICTION AND TOP APPLICANT ANALYSIS 94
FIGURE 20 DIGITAL BIOMARKERS MARKET: TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS), JANUARY 2015–APRIL 2026 95
FIGURE 21 MARKET POTENTIAL OF AI/GEN AI ON DIGITAL BIOMARKERS ACROSS INDUSTRIES 98
FIGURE 22 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS 100
FIGURE 23 TRIAL PHASES WITH DIGITAL ENDPOINTS 151
FIGURE 24 NORTH AMERICA: DIGITAL BIOMARKERS MARKET SNAPSHOT 165
FIGURE 25 ASIA PACIFIC: DIGITAL BIOMARKERS MARKET SNAPSHOT 226
FIGURE 26 DIGITAL BIOMARKERS MARKET: REVENUE ANALYSIS OF KEY PLAYERS 288
FIGURE 27 DIGITAL BIOMARKERS MARKET SHARE ANALYSIS OF KEY PLAYERS (2025) 289
FIGURE 28 DIGITAL BIOMARKERS MARKET: BRAND COMPARATIVE ANALYSIS 292
FIGURE 29 EV/EBITDA OF KEY VENDORS 293
FIGURE 30 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR
STOCK BETA OF KEY VENDORS 293
FIGURE 31 DIGITAL BIOMARKERS MARKET: COMPANY EVALUATION MATRIX (2025) 295
FIGURE 32 DIGITAL BIOMARKERS MARKET: COMPANY FOOTPRINT 296
FIGURE 33 DIGITAL BIOMARKERS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 303
FIGURE 34 IXICO PLC: COMPANY SNAPSHOT (2025) 310
FIGURE 35 CONNEQT HEALTH: COMPANY SNAPSHOT (2025) 330
FIGURE 36 LUNIT INC.: COMPANY SNAPSHOT (2025) 339
FIGURE 37 RESEARCH DESIGN 380
FIGURE 38 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE,
DESIGNATION, AND REGION 384
FIGURE 39 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 386
FIGURE 40 BOTTOM-UP APPROACH 387
FIGURE 41 TOP-DOWN APPROACH 388
FIGURE 42 CAGR PROJECTIONS BASED ON DROC ANALYSIS OF
DIGITAL BIOMARKERS INDUSTRY 389
FIGURE 43 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 389
FIGURE 44 DATA TRIANGULATION METHODOLOGY 391

---

---